

# CI Global Health Sciences Corporate Class



Class Z USD

Not available to retail investors / for approved investors only

AS AT AUGUST 31, 2020

## FUND OVERVIEW

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

## FUND DETAILS

Inception date	August 2009
Total net assets (\$CAD) As at 2020-08-31	\$181.6 million
NAVPS	\$19.1038
MER (%) As at 2020-03-31	2.45
Management fee (%)	2.00
Asset class	Sector Equity
Currency	USD
Minimum investment	\$500 initial / \$25 additional
Distribution frequency	Quarterly
Last distribution	\$0.1428

## Risk rating<sup>2</sup>




## FUND CODES


Z	ISC 2926 DSC 2927 LL 2929
A	ISC 301 DSC 401 LL 1401
F	324
P	90324
Y	4926

## PERFORMANCE<sup>1</sup>

### Growth of \$10,000 (since inception date)



### Calendar year performance



### Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
1.6%	6.3%	2.9%	9.6%	23.2%	3.1%	-0.1%	10.2%	9.6%

\*Since inception date

## DISTRIBUTION HISTORY<sup>3</sup>

Payable date	Total	Payable date	Total
2020-06-26	0.1428	2019-03-22	0.3484
2020-03-20	0.3339	2018-12-14	0.0547
2019-12-13	0.2092	2018-09-14	0.0556
2019-09-27	0.2341	2018-06-22	0.0546
2019-06-21	0.2210	2018-03-23	0.3911

## MANAGEMENT TEAM



Altrinsic Global Advisors follows a fundamental value approach to seek out high-quality undervalued companies worldwide. Altrinsic was founded by John Hock and associates and a sub-advisor to CI Investments Inc., a subsidiary of CI Financial Corp. CI Financial Corp. holds a minority interest in Altrinsic Global Advisors.



Andrew Waight

# CI Global Health Sciences Corporate Class

Class Z USD

Not available to retail investors / for approved investors only



AS AT AUGUST 31, 2020

## PORTFOLIO ALLOCATIONS<sup>5</sup>

Asset allocation	(%)	Sector allocation	(%)	Geographic allocation	(%)
US Equity	61.96%	Healthcare	85.27%	United States	64.68%
International Equity	32.80%	Consumer Services	7.76%	Japan	12.24%
Cash and Equivalents	3.79%	Cash and Cash Equivalent	3.79%	Germany	6.90%
Canadian Equity	1.48%	Financial Services	2.42%	Switzerland	3.41%
Other	-0.03%	Real Estate	0.79%	France	2.91%
		Other	-0.03%	Canada	2.55%
				United Kingdom	2.54%
				Other	2.14%
				Ireland	1.45%
				Singapore	1.18%

## TOP HOLDINGS

	Sector	(%)
1. Bristol-Myers Squibb Co	Drugs	6.03%
2. SeaSpine Holdings Corp	Diversified Healthcare	6.00%
3. Alexion Pharmaceuticals Inc	Drugs	5.74%
4. Takeda Pharmaceutical Co Ltd	Drugs	5.66%
5. Merit Medical Systems Inc	Drugs	5.09%
6. CVS Health Corp	Retail	4.91%
7. Ionis Pharmaceuticals Inc	Drugs	4.54%
8. Fresenius Medical Care AG & Co KGaA	Healthcare Services	4.26%
9. Intercept Pharmaceuticals Inc	Drugs	3.90%
10. Astellas Pharma Inc	Drugs	3.73%
11. Novartis AG	Healthcare Equipment	3.41%
12. Biogen Idec Inc	Drugs	3.31%
13. Sangamo BioSciences Inc	Diversified Healthcare	3.30%
14. Sanofi SA	Drugs	2.91%
15. Sugi Holdings Co Ltd	Retail	2.85%

Note: This page is not complete without disclaimers on the next page.

Over 35,000 financial advisors have chosen CI Investments as a partner. We believe that Canadians have the best opportunity for investment success by using the services of a professional financial advisor. [Learn more at ci.com](https://www.ci.com).

<sup>1</sup> Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns net of fees and expenses payable by the fund (except for figures of one year or less, which are simple total returns) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

<sup>2</sup> The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

<sup>3</sup> Please refer to the fund's simplified prospectus for distribution information.

<sup>5</sup> Portfolio allocations will fluctuate over the life of the mutual fund as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

Certain statements contained in this communication are based in whole or in part on information provided by third parties and CI has taken reasonable steps to ensure their accuracy.

The rates of return are used only to illustrate the effects of the compound growth rate and are not intended to reflect future values or returns on investment in an investment fund.

The "Growth of \$10,000" chart shows the final value of a hypothetical \$10,000 investment in securities in this class of the fund as at the end of the investment period indicated and is not intended to reflect future values or returns on investment in such securities.

Management Expense Ratio ("MER") represents the trailing 12-month management expense ratio, which reflects the cost of running the fund, inclusive of applicable taxes including HST, GST and QST (excluding commissions and other portfolio transaction costs) as a percentage of daily average net asset value the period, including the fund's proportionate share of any underlying fund(s) expenses, if applicable. The MER is reported in each fund's Management Report of Fund Performance ("MRFP"). MRFPs can be found within the Documents tab on ci.com.

CI Investments® and the CI Investments design are registered trademarks of CI Investments Inc. "Trusted Partner in Wealth™" is a trademark of CI Investments Inc. ©CI Investments Inc. 2020. All rights reserved.

Published September 2020